BRAIN Biotech Forecast, price target & analysts
BRAIN Biotech Target price 2025 - Analyst rating & recommendation
BRAIN Biotech Classifications & Recommendation:
BRAIN Biotech Price Target
| Target Price | €6.56 |
| Price | €2.36 |
| Potential |
178.07%
register free of charge
|
| Number of Estimates | 4 |
|
4 Analysts have issued a price target BRAIN Biotech 2026 .
The average BRAIN Biotech target price is €6.56.
This is
178.07%
register free of charge
€10.00
323.73%
register free of charge
€4.80
103.39%
register free of charge
|
|
| A rating was issued by 4 analysts: 3 Analysts recommend BRAIN Biotech to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the BRAIN Biotech stock has an average upside potential 2026 of
178.07%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2028
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 54.63 | 60.82 |
| 1.28% | 11.33% | |
| EBITDA Margin | -9.43% | 5.24% |
| 153.25% | 155.58% | |
| Net Margin | -20.40% | -9.09% |
| 35.95% | 55.44% |
4 Analysts have issued a sales forecast BRAIN Biotech 2025 . The average BRAIN Biotech sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an BRAIN Biotech EBITDA forecast 2025. The average BRAIN Biotech EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
3 BRAIN Biotech Analysts have issued a net profit forecast 2025. The average BRAIN Biotech net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2028
| Sep '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | -0.51 | -0.25 |
| 34.21% | 50.98% | |
| P/E | negative | |
| EV/Sales | 0.93 |
3 Analysts have issued a BRAIN Biotech forecast for earnings per share. The average BRAIN Biotech EPS is
This results in the following potential growth metrics and future valuations:
Current BRAIN Biotech Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BAADER HELVEA EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Nov 12 2024 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Nov 10 2024 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | Nov 04 2024 |
| EQUI.TS |
Locked
➜
Locked
|
Locked | Sep 12 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
BAADER HELVEA EQUITY RESEARCH:
Locked
➜
Locked
|
Nov 12 2024 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Nov 10 2024 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Nov 04 2024 |
|
Locked
EQUI.TS:
Locked
➜
Locked
|
Sep 12 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
